naproxen has been researched along with Bladder Cancer in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Grubbs, CJ; Juliana, MM; Lubet, RA; Miller, MS; Moeinpour, FL; Mohammed, A; Sei, S; Shoemaker, RH; Suen, CS | 1 |
| Bode, AM; Chen, H; Dong, Z; Grubbs, CJ; Huang, Z; Kim, JE; Kim, MS; Langfald, A; Lim, DY; Lubet, RA | 1 |
| Bode, AM; Boring, D; Grubbs, CJ; Kim, MS; Lu, Y; Lubet, RA; Margaret Juliana, M; Milne, GL; Nicastro, HL; Steele, VE; You, M | 1 |
| Bode, A; Boring, DL; Grubbs, CJ; Juliana, MM; Lubet, RA; Minasian, L; Scheiman, JM; Steele, VE; White, J | 1 |
| Boring, D; Grubbs, CJ; Juliana, MM; Kopelovich, L; Lubet, RA; Patlolla, J; Rao, CV; Steele, VE; Zhang, Y | 1 |
| Grubbs, CJ; Juliana, MM; Lubet, RA; Steele, VE | 1 |
6 other study(ies) available for naproxen and Bladder Cancer
| Article | Year |
|---|---|
Combination of Erlotinib and Naproxen Employing Pulsatile or Intermittent Dosing Profoundly Inhibits Urinary Bladder Cancers.
Topics: Animals; Anticarcinogenic Agents; Butylhydroxybutylnitrosamine; Carcinogens; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Naproxen; Neoplasm Recurrence, Local; Neoplasms, Experimental; Pulse Therapy, Drug; Rats; Time Factors; Time-to-Treatment; Urinary Bladder; Urinary Bladder Neoplasms | 2020 |
Naproxen induces cell-cycle arrest and apoptosis in human urinary bladder cancer cell lines and chemically induced cancers by targeting PI3K.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Female; Humans; Naproxen; Neoplasms, Experimental; Phosphoinositide-3 Kinase Inhibitors; Rats; Rats, Inbred F344; Urinary Bladder Neoplasms | 2014 |
Preventive effects of NSAIDs, NO-NSAIDs, and NSAIDs plus difluoromethylornithine in a chemically induced urinary bladder cancer model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Chemoprevention; Drug Evaluation, Preclinical; Eflornithine; Female; Naproxen; Neoplasms, Experimental; Nitric Oxide; Rats; Rats, Inbred F344; Sulindac; Urinary Bladder Neoplasms | 2014 |
Prevention of chemically induced urinary bladder cancers by naproxen: protocols to reduce gastric toxicity in humans do not alter preventive efficacy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Western; Butylhydroxybutylnitrosamine; Carcinogens; Female; Fluorescent Antibody Technique; Humans; Mice; Naproxen; Rats; Rats, Inbred F344; Stomach; Urinary Bladder Neoplasms | 2015 |
Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers.
Topics: Alkylating Agents; Animals; Anti-Inflammatory Agents, Non-Steroidal; Azoxymethane; Butylhydroxybutylnitrosamine; Carcinogens; Colonic Neoplasms; Diet; Female; Male; Mammary Neoplasms, Experimental; Methylnitrosourea; Naproxen; Nitric Oxide Donors; Precancerous Conditions; Rats; Rats, Inbred F344; Rats, Sprague-Dawley; Urinary Bladder Neoplasms | 2009 |
Screening agents for preventive efficacy in a bladder cancer model: study design, end points, and gefitinib and naproxen efficacy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Cyclooxygenase Inhibitors; Disease Models, Animal; Drug Screening Assays, Antitumor; Female; Gefitinib; Naproxen; Quinazolines; Rats; Rats, Inbred F344; Research Design; Resveratrol; Stilbenes; Urinary Bladder Neoplasms | 2010 |